bioAffinity Technologies(BIAF) - 2024 Q1 - Quarterly Results

News Release More than 547% annualized growth rate for CyPath Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original 2024 forecast Key Highlights "CyPath Lung is positioned to set a new standard in the early detection of lung cancer – a market projected to reach $4.7 billion by 2030," Zannes continued. "As we continue to scale our operations and enhance our offerings, our focus remains steadfast on improving patient outcomes and delivering shareholder value. With M ...